Scholarlink

<p>Type 2 diabetes mellitus (T2D) affects over 460 million people worldwide and profoundly diminishes their quality of life. Its onset is driven by obesity, sedentary behavior, and genetic predisposition, leading to insulin resistance, progressive beta-cell dysfunction, and complications such as cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). Effective management requires therapies that extend beyond glycemic control to address these interconnected risks. Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has demonstrated remarkable efficacy in clinical studies, particularly the SURPASS trials. It achieved a reduction in HbA1c of up to 2.3% and body weight losses exceeding 22% over 72 weeks. Additional benefits include improvement in blood pressure, lipid levels, and inflammatory markers, with potential benefit in NAFLD. Pharmacists play a vital role in translating these benefits into practice by counselling patients on safe use, managing adverse effects, and supporting adherence. Their involvement bridges the gap between trial evidence and real-world outcomes. This review examines the dual mechanism of tirzepatide, its broader metabolic effects, and the critical role of pharmacists in optimizing its use. With pharmacist-led care, tirzepatide has the potential to transform diabetes management across diverse populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Revolutionizing type 2 diabetes management: the role of the pharmacist in unlocking the potential of tirzepatide

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月17日

查看全文
  • David Banji,
  • Saeed Alshahrani,
  • Moaddey Alfarhan,
  • Otilia J. F. Banji

摘要

Type 2 diabetes mellitus (T2D) affects over 460 million people worldwide and profoundly diminishes their quality of life. Its onset is driven by obesity, sedentary behavior, and genetic predisposition, leading to insulin resistance, progressive beta-cell dysfunction, and complications such as cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). Effective management requires therapies that extend beyond glycemic control to address these interconnected risks. Tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has demonstrated remarkable efficacy in clinical studies, particularly the SURPASS trials. It achieved a reduction in HbA1c of up to 2.3% and body weight losses exceeding 22% over 72 weeks. Additional benefits include improvement in blood pressure, lipid levels, and inflammatory markers, with potential benefit in NAFLD. Pharmacists play a vital role in translating these benefits into practice by counselling patients on safe use, managing adverse effects, and supporting adherence. Their involvement bridges the gap between trial evidence and real-world outcomes. This review examines the dual mechanism of tirzepatide, its broader metabolic effects, and the critical role of pharmacists in optimizing its use. With pharmacist-led care, tirzepatide has the potential to transform diabetes management across diverse populations.